Merocrit contains Meropenem that is a broad-spectrum carbapenem antibiotic. It exhibits bactericidal activity by inhibiting bacterial cell wall synthesis. It readily penetrates the cell wall of most of the bacteria to reach penicillin-binding-protein (PBP) targets to destroy the bacteria. Meropenem continues to be an important option for the treatment of serious bacterial infections in hospitalized patients.
It is approved for use in complicated intra-abdominal infection, complicated skin and skin structure infection and bacterial meningitis in the United States, and in most other countries for pneumonia, septicaemia, bacterial meningitis, complicated urinary tract infection, obstetric and gynaecological infections, in cystic fibrosis patients with pulmonary exacerbations, severe community-acquired pneumonia and many other serious illnesses.
Merocrit is indicated for the treatment of the following infections in adults and children above 3 months of age:
Pneumonia, including community-acquired pneumonia and nosocomial pneumonia
Complicated urinary tract infections
Complicated intra-abdominal infections (complicated appendicitis and peritonitis)
Intra-and post-partum infections
Complicated skin and skin structure infections
Broncho-pulmonary infections in cystic fibrosis
Acute bacterial meningitis
Merocrit is a product from Cipla limited which is an Indian multinational pharmaceutical and biotechnology company. It is primarily into development of medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, depression and other medical conditions. The company’s goal is ensuring that no patient shall be denied access to high quality and affordable medicines and support with the vision to make India self-sufficient in health care.
This antibiotic is used for a variety of severe bacterial infections.
Some of them are explained below-
Pneumonia is an infection that inflames the air sacs in one or both lungs. The air sacs may fill with fluid or pus (purulent material), causing cough with phlegm or pus, fever, chills, and difficulty breathing
Hospital-acquired pneumonia: Some people catch pneumonia during a hospital stay for another illness. Hospital-acquired pneumonia can be serious because the bacteria causing it may be more resistant to antibiotics and because the people who get it are already sick. People who are on breathing machines (ventilators), often used in intensive care units, are at higher risk of this type of pneumonia.
Infective endocarditis (IE)
Infective endocarditis (IE), also called bacterial endocarditis (BE), is an infection caused by bacteria that enter the bloodstream and settle in the heart lining, a heart valve or a blood vessel. IE is uncommon, but people with some heart conditions have a greater risk of developing it.
Septicemia is a life-threatening complication of an infection. Sepsis occurs when chemicals released in the bloodstream to fight an infection trigger inflammation throughout the body. This can cause a cascade of changes that damage multiple organ systems, leading them to fail, sometimes even resulting in death.
As directed by your Physician.
As directed by your Physician.
Adverse Reactions/ Side Effects
Diarrhoea, nausea, vomiting, abdominal pain; headache; constipation; rash, pruritus, uticaria; apnoea; phlebitis, thrombophlebitis, swelling and pain at inj site; disturbances in LFTs (may cause increases in serum transaminases, alkaline phosphatase, lactic dehydrogenase). Rarely: erythema multiforme; eosinophilia, thrombocytopenia, leucopenia, neutropenia; seizures and CNS effects reported in patients with underlying CNS disorders or renal impairment.
Meropenem should be administered to patients with allergy to Penicillin antibiotics, Cephalosporin, Imipenem and Meropenem. Meropenem is contraindicated in patients with renal diseases, brain tumor, head injury and seizures. An adjusted dosage may be needed in such patients.
History of hypersensitivity to carbapenem, pencillins or other β-lactam antibiotics; infants <3 months; renal insufficiency; neurological disorders; pregnancy, lactation. Not recommended for use in MRSA.
USFDA pregnancy category B. Meropenem may not cause harm to an unborn foetus. Before Meropenem treatment, the patient should discuss with the physician, if they are planning for a pregnancy.
Meropenem and Lactation- It is unclear whether the drug could pass through the breast milk to a breast feeding a baby. Consult your physician before taking Meropenem, if you are nursing mother.
Meropenem and Children- Safety and efficacy in children 3 months of age and younger not established.
Meropenem and Geriatic- Use care in dose selection because elderly patients are more likely to have decreased renal function; monitor renal function.
Serum levels may be increased by probenecid. May reduce serum valproic acid levels; sub-therapeutic levels may be reached in some patients.
Mechanism of Action
Meropenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Gram-positive and Gram-negative bacteria through binding to multiple penicillin-binding proteins (PBPs).